Literature DB >> 35642329

DOG1 overexpression is associated with mismatch repair deficiency and BRAF mutations but unrelated to cancer progression in colorectal cancer.

Kristina Jansen1,2, Martina Kluth1, Niclas C Blessin1, Claudia Hube-Magg1, Michael Neipp3, Hamid Mofid4, Hannes Lárusson4, Thies Daniels5, Christoph Isbert6, Stephan Coerper7, Daniel Ditterich8, Holger Rupprecht9, Albert Goetz10, Christian Bernreuther1, Guido Sauter1, Ria Uhlig1, Waldemar Wilczak1, Ronald Simon1, Stefan Steurer1, Eike Burandt1, Daniel Perez2, Jakob R Izbicki2, Frank Jacobsen1, Till S Clauditz1, Andreas H Marx1,11, Till Krech1,12.   

Abstract

INTRODUCTION: The transmembrane channel protein DOG1 (Discovered on GIST1) is normally expressed in the gastrointestinal interstitial cells of Cajal and also in gastrointestinal stroma tumors arising from these cells. However, there is also evidence for a relevant role of DOG1 expression in colorectal cancers. This study was undertaken to search for associations between DOG1 expression and colon cancer phenotype and key molecular alterations.
METHODS: A tissue microarray containing samples from more than 1,800 colorectal cancer patients was analyzed by immunohistochemistry.
RESULTS: DOG1 immunostaining was detected in 503 (30.2%) of 1,666 analyzable colorectal cancers and considered weak in 360 (21.6%), moderate in 78 (4.7%), and strong in 65 (3.9%). Strong DOG1 immunostaining was associated with advanced pT stage (p=0.0367) and nodal metastases (p=0.0145) but these associations were not retained in subgroups of 1,135 mismatch repair proficient and 86 mismatch repair deficient tumors. DOG1 positivity was significantly linked to several molecular tumor features including mismatch repair deficiency (p=0.0034), BRAF mutations (p<0.0001), nuclear p53 accumulation (p=0.0157), and PD-L1 expression (p=0.0199) but unrelated to KRAS mutations and the density of tumor infiltrating CD8 positive lymphocytes.
CONCLUSION: Elevated DOG1 expression is frequent in colorectal cancer and significantly linked to important molecular alterations. However, DOG1 overexpression is largely unrelated to histopathological parameters of cancer aggressiveness and may thus not serve as a prognostic parameter for this tumor entity. ©The Author(s) 2022. Open Access. This article is licensed under a Creative Commons CC-BY International License.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35642329     DOI: 10.14670/HH-18-475

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.130


  58 in total

Review 1.  The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.

Authors:  Afsane Bahrami; AmirReza Hesari; Majid Khazaei; Seyed Mahdi Hassanian; Gordon A Ferns; Amir Avan
Journal:  J Cell Physiol       Date:  2017-05-23       Impact factor: 6.384

2.  Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling.

Authors:  Adrian Britschgi; Anke Bill; Heike Brinkhaus; Christopher Rothwell; Ieuan Clay; Stephan Duss; Michael Rebhan; Pichai Raman; Chantale T Guy; Kristie Wetzel; Elizabeth George; M Oana Popa; Sarah Lilley; Hedaythul Choudhury; Martin Gosling; Louis Wang; Stephanie Fitzgerald; Jason Borawski; Jonathan Baffoe; Mark Labow; L Alex Gaither; Mohamed Bentires-Alj
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

3.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.

Authors:  Mahul B Amin; Frederick L Greene; Stephen B Edge; Carolyn C Compton; Jeffrey E Gershenwald; Robert K Brookland; Laura Meyer; Donna M Gress; David R Byrd; David P Winchester
Journal:  CA Cancer J Clin       Date:  2017-01-17       Impact factor: 508.702

Review 4.  RAS mutation: site of disease and recurrence pattern in colorectal cancer.

Authors:  Pierre E Bonnot; Guillaume Passot
Journal:  Chin Clin Oncol       Date:  2019-10

5.  Functional role of the Ca²⁺-activated Cl⁻ channel DOG1/TMEM16A in gastrointestinal stromal tumor cells.

Authors:  Erik Berglund; Pinar Akcakaya; David Berglund; Fredrik Karlsson; Vladana Vukojević; Linkiat Lee; Darko Bogdanović; Weng-Onn Lui; Catharina Larsson; Jan Zedenius; Robin Fröbom; Robert Bränström
Journal:  Exp Cell Res       Date:  2014-05-10       Impact factor: 3.905

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Prevalence of proliferating CD8+ cells in normal lymphatic tissues, inflammation and cancer.

Authors:  Niclas C Blessin; Raed Abu-Hashem; Tim Mandelkow; Wenchao Li; Ronald Simon; Claudia Hube-Magg; Christina Möller-Koop; Melanie Witt; Alice Schmidt; Franziska Büscheck; Christoph Fraune; Andreas M Luebke; Katharina Möller; Frank Jacobsen; Florian Lutz; Maximilian Lennartz; Stefan Steurer; Guido Sauter; Doris Höflmayer; Maria Christina Tsourlakis; Andrea Hinsch; Eike Burandt; Waldemar Wilczak; Sarah Minner; Till S Clauditz
Journal:  Aging (Albany NY)       Date:  2021-06-03       Impact factor: 5.682

8.  ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer.

Authors:  Anke Bill; Abraham Gutierrez; Sucheta Kulkarni; Carolyn Kemp; Debora Bonenfant; Hans Voshol; Umamaheswar Duvvuri; L Alex Gaither
Journal:  Oncotarget       Date:  2015-04-20

Review 9.  KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician.

Authors:  Vlad-Adrian Afrăsânie; Mihai Vasile Marinca; Teodora Alexa-Stratulat; Bogdan Gafton; Marius Păduraru; Anca Maria Adavidoaiei; Lucian Miron; Cristina Rusu
Journal:  Radiol Oncol       Date:  2019-09-24       Impact factor: 2.991

10.  Expression of ANO1/DOG1 is associated with shorter survival and progression of breast carcinomas.

Authors:  Jun Sang Bae; Jeong Yeol Park; See-Hyoung Park; Sang Hoon Ha; Ae Ri An; Sang Jae Noh; Keun Sang Kwon; Sung Hoo Jung; Ho Sung Park; Myoung Jae Kang; Kyu Yun Jang
Journal:  Oncotarget       Date:  2017-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.